TY  - JOUR
AU  - Daudén, Esteban
AU  - Carretero, Gregorio
AU  - Rivera, Raquel
AU  - Ferrándiz, Carlos
AU  - Llamas-Velasco, Mar
AU  - de la Cueva, Pablo
AU  - Belinchón, Isabel
AU  - Gómez-García, Francisco José
AU  - Herrera-Acosta, Enrique
AU  - Ruiz-Genao, Diana Patricia
AU  - Ferrán-Farrés, Marta
AU  - Alsina, Mercè
AU  - Baniandrés-Rodríguez, Ofelia
AU  - Sánchez-Carazo, José Luis
AU  - Sahuquillo-Torralba, Antonio
AU  - Fernández-Freire, Lourdes Rodriguez
AU  - Vilar-Alejo, Jaime
AU  - García-Donoso, Carmen
AU  - Carrascosa, José Manuel
AU  - Herrera-Ceballos, Enrique
AU  - López-Estebaranz, José Luis
AU  - Botella-Estrada, Rafael
AU  - Segovia-Muñoz, Eva
AU  - Descalzo, Miguel Angel
AU  - García-Doval, Ignacio
AU  - BIOBADADERM Study Group
PY  - 2020
DO  - 10.1016/j.jaad.2020.03.033
UR  - http://hdl.handle.net/10668/15285
T2  - Journal of the American Academy of Dermatology
AB  - Registry studies broadly describing the safety of systemic drugs in psoriasis are needed. To describe the safety findings of the systemic drugs acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, and...
LA  - en
KW  - adverse effects
KW  - anti-TNF
KW  - anti-inflammatory agents
KW  - biologic agents
KW  - immunosuppressive agents
KW  - long-term follow-up
KW  - pharmacovigilance
KW  - prospective cohort
KW  - psoriasis/drug therapy
KW  - registries
KW  - safety
KW  - Adult
KW  - Aged
KW  - Biological Therapy
KW  - Cohort Studies
KW  - Female
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Psoriasis
KW  - Registries
KW  - Spain
KW  - Time Factors
TI  - Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry.
TY  - research article
VL  - 83
ER  -